AR166 / Y-Biologics - LARVOL DELTA

AR166, a first-in-class PD-1xLAG-3xIL-2v tri-specific immunocytokine delivering Cis-acting IL-2v to overcome immune checkpoint inhibitor resistance (AACR 2026) - "AR166 elicited durable tumor regression in a tumor rechallenge model, suggesting tumor-specific immune memory. AR166 achieved favorable safety and pharmacokinetic profiles in both mice and cynomolgus monkeys, supporting its broad therapeutic window.Our findings show that AR166, a first-in-class PD-1xLAG-3xIL-2v tri-specific, can exceed the efficacy of both PD-1 inhibitors and PD-1xIL-2v with good safety."

Checkpoint inhibition • IO biomarker • Trispecific • Oncology • CD8 • IL2 • LAG3

Y-Biologics said on the 7th that it signed a contract manufacturing and development (CDMO) deal with China’s WuXi Biologics to develop new drugs using its next-generation triple-target immuno-oncology platform, “Multi-AbKine.“ (Chosun Biz) - "Y-Biologics is currently developing three pipelines in parallel based on the Multi-AbKine platform. Among them, 'AR170' is being prepared for submission of an investigational new drug (IND) application for global clinical trials, including in the United States, in the first half of 2027, and 'AR166' in the second half of 2027."

IND • Licensing / partnership • Oncology